FROM BURDEN TO RELIEF: A REVIEW ON DUPILUMAB AND ITS INFLUENCE ON QUALITY OF LIFE IN ATOPIC DERMATITIS
DOI:
https://doi.org/10.63330/armv2n4-017Keywords:
Atopic Dermatitis, Biological Therapy, Pruritus, Quality of Life, Systemic TreatmentAbstract
Atopic dermatitis is a chronic inflammatory skin disease characterized by intense itching, recurrent eczematous lesions, and a significant impact on patients' quality of life. The condition has a multifactorial etiology, involving alterations in the skin barrier, genetic predisposition, environmental factors, and dysregulation of the immune response, especially mediated by the Th2 pathway. In mild to moderate cases, treatment is mainly based on topical therapies; however, in moderate to severe cases, systemic therapies may be necessary. In this context, dupilumab emerges as an innovative therapeutic alternative, being a monoclonal antibody that acts by blocking interleukins IL-4 and IL-13, cytokines involved in the inflammatory process of the disease. This study aims to analyze the efficacy of dupilumab in the treatment of moderate to severe atopic dermatitis and its impact on improving symptoms and quality of life in patients. The studies analyzed demonstrate that the use of dupilumab is associated with a significant reduction in disease severity, decreased pruritus, and improved clinical and quality of life indicators. Therefore, it is observed that the medication represents an important advance in the therapeutic management of atopic dermatitis, contributing to disease control and improved patient well-being.
Downloads
References
DE BRUIN-WELLER, M. et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III trial (LIBERTY AD CAFÉ). The Lancet, v. 391, n. 10139, p. 2280–2290, 2018. Disponível em: https://pubmed.ncbi.nlm.nih.gov/29193016/. Acesso em: 26 set. 2025.
GOODERHAM, M. J.; HONG, C. H.; ESHTIAGHI, P.; PAPP, K. A. Dupilumab: a review of its use in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology, v. 78, n. 3, p. S28–S36, 2018. DOI: 10.1016/j.jaad.2017.12.022. Acesso em: 15 out. /2025
LIMÃO, Rita; BRÁS, Rita; NETO, Marta; FERNANDES, Rosa Anita; ABREU, Cristina Lopes; COSTA, Célia; COSME, Joana; DUARTE, Fátima; MENDES, Ana; SANTOS, Amélia Spínola; FERREIRA, Manuel Branco; PEDRO, Elisa; LOPES, Anabela. Controlo a longo prazo da dermatite atópica em doentes sob terapêutica com dupilumab – Um estudo multicêntrico / Long-term control of atopic dermatitis in patients treated with dupilumab – A multicentric study. Revista da Sociedade Portuguesa de Dermatologia e Venereologia, v. 82, n. 3, p. 257–268, 2024. Acesso em: 27 out. 2025.
MALTA, Hatila Alicia Gonçalves; COSTA, Natália Cruz Pessanha; OLIVEIRA FILHO, Cézar Romero de; SOARES UNTER, Vanessa Silva; NASCIMENTO, Thaline de Oliveira. O impacto do prurido na qualidade de vida: uma revisão sobre doenças pruriginosas. Revista Ibero-Americana de Humanidades, Ciências e Educação (REASE), v. 10, n. 10, 2024. DOI: https://doi.org/10.51891/rease.v10i10.16355. Acesso em: 23 out. 2025.
MARIANO, Isabella Andrade; MARQUES, Andressa Souza; BARBOSA, Caio Ribeiro; VIEIRA, Henrique Pereira Osta. Dermatite atópica na infância: uma revisão abrangente sobre a epidemiologia, fisiopatogênese, fatores de risco, diagnóstico, abordagem medicamentosa, cuidados com a pele, complicações, prognóstico e qualidade de vida. Brazilian Journal of Health Review, v. 7, n. 2, p. –, 2024. DOI: 10.34119/bjhrv7n2-049. Acesso em: 24 out.2025.
RODRIGUES, Maria A.; NOGUEIRA, Miguel; TORRES, Tiago. Dupilumab para dermatite atópica: evidências até o momento. Jornal and Books on Medicine, 2021. Disponível em: https://www.journalandbooksonmedicine.com/dupilumabe-para-dermatite-atopica-evidencias. Acesso em: 15 out. 2025.
Silverberg, Jonathan I et al. “Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study.” Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology, vol. 121,3 (2018): 340-347. doi:10.1016/j.anai.2018.07.006. Acesso em: 26 set. 2025.
TROLEZ, C.; RESENDE, AJGS; FERREIRA, IP e; NUNES, JB Dermatite atópica: avanços na fisiopatologia, diagnóstico e estratégias terapêuticas baseadas em evidências. Revista Brasileira de Revisão de Saúde , [S. l.] , v. 4, pág. e81443, 2025. DOI: 10.34119/bjhrv8n4-193. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/81443. Acesso em: 16 out. 2025.
WEIDINGER, S.; NOVAK, N.; et al. Atopic dermatitis. The Lancet, v. 387, n. 10023, p. 1109-1122, 2016. DOI: 10.1016/S0140-6736(15)00149-X. Acesso em: 30 set. 2025
WERFEL, T. et al. Eficácia e segurança do dupilumab para dermatite atópica moderada a grave: uma revisão sistemática para as diretrizes de produtos biológicos da EAACI. Journal of Allergy and Clinical Immunology, v. 138, n. 2, p. 336–349, 2016. DOI: https://doi.org/10.1111/all.14510 Acesso em: 25 out. 2025.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
